Diverse technologies have a surprising number of common threads, whether in the technologies themselves or in the clinical applications. For this reason, manufacturers need to consider that: 1. A technology platform can be the launchpad for products in clinically diverse areas. Case in point, cell therapy, which as a fundamental scientific discipline can have uses [...]
FDA Approves For Permanent Treatment Of Advanced Heart Failure Assist Device Pioneered By Texas Heart Institute At St. Luke’s Episcopal Hospital. See Link Although designed as a bridge-to-transplant device, the HeartMate II has proven itself sufficiently in trials to warrant its approval as a permanent device. Designed by the Texas Heart Institute, the continuous flow left [...]
With the FDA's approval of Medtronic's Melody Transcatheter Pulmonary Valve and Ensemble Delivery System (see link), another step has been made toward eliminating traditional surgery — at least that's the idea. The ability to implant a valve via a percutaneous procedure advances the art of less invasive intervention in ways akin to laparoscopic surgery, albeit at [...]
Dr. Julio Palmaz, who with Dr. Richard Schatz patented the balloon-expandable stent, believes that, while the market for stents has evolved from bare metal stents to drug-eluting stents (DES), the inevitable limitation of DES will be that they lead to inflammatory response and that their real drawback is that they create a barrier between tissue [...]
(The global market for coronary stents worldwide is assessed in the MedMarket Diligence report #C245, "Worldwide Market for Drug-Eluting, Bare Metal and Other Coronary Stents, 2008-2017.") The market for coronary stents in Asia and the Pacific region contains both China (early technology adopters) and Japan (with a longer regulatory approval cycle), which generated a combined [...]
The global market for stents in the treatment coronary artery disease, while dominated by drug-eluting stents, continues to also be comprised of a diversity of stent technologies. The market is evolving steadily as manufacturers aggressively seek optimal anti-restenosis, characterized by the goal of low rates of repeat revascularization. As with many medical technologies, prices, availability [...]
Coronary stent technology development trends include the stimulation of vessel wall healing following revascularization. OrbusNeich has developed its "Genous", a patented endothelial progenitor cell (EPC) capture technology designed and shown to promote the accelerated natural healing of the vessel wall following stenting. See link on OrbusNeich Genous recent data. The MedMarket Diligence report #C245 [...]
Translation: Drug-eluting stents are to bare metal stents as bare metal stents were to percutaneous transluminal coronary angioplasty alone. In the September 1 post on the meta-analysis by researchers at Tuft Medical Center, we noted the overall findings in general terms of the value of drug-eluting stents compared to bare metal stents. It is worthwhile to [...]
The global coronary stent market faces continued growth, development and competition from a wide range of technology types and competitors. The market is detailed in a new report from MedMarket Diligence. FOR IMMEDIATE RELEASE PRLog (Press Release) – Aug 31, 2009 – Since the advent of coronary stents, followed by the emergence of drug eluting [...]
While coronary stents were first developed in the 1980s and have been on the commercial market (i.e., FDA approved) since 1994, the technologies and materials used to create the devices are improving every day. In addition, innovative technology is bringing new classes of devices (e.g., fully degradable stents) to market, technologies that grow the market [...]
Contact:
